First Center in Hong Kong Treats Patients with CyberKnife® and TomoTherapy®
Hong Kong Adventist Oncology Center Offers Full Spectrum of Disease Treatment
with State-of-the-art Technologies
SUNNYVALE, Calif., March 11, 2013
SUNNYVALE, Calif., March 11, 2013 /PRNewswire/ --Accuray Incorporated
(Nasdaq: ARAY), announced today that Hong Kong Adventist Oncology Center, the
first center locally to offer both the CyberKnife® Robotic Radiosurgery and
TomoTherapy® Systems, hosted its official opening ceremony last week. Hong
Kong Adventist Oncology Center is a newly built cancer center that was
designed to accommodate both systems. Their TomoTherapy System was installed
late last year and their CyberKnife System was installed in September 2006.
"We are pleased to offer the most flexible, precise solutions for radiation
treatment planning and delivery that enable us to deliver personalized
treatments to a wide range of patients," said Dr. Stephen Law, clinical
director of Hong Kong Adventist Oncology Center. "The CyberKnife and
TomoTherapy Systems allow our clinicians to create specialized treatments
ranging from high-precision radiosurgery for early-stage and localized disease
to image-guided, intensity-modulated radiation therapy (IG-IMRT) for more
advanced disease throughout the body."
"Our two leading-edge treatment solutions – the CyberKnife and the TomoTherapy
Systems – satisfy all the external beam radiation delivery needs of an
oncology department and give clinicians flexible, individualized treatment
options to use in their pursuit of optimal treatment outcomes." said Lionel
Hadjadjeba, general manager EIMEA and senior vice president of International
Business at Accuray. "The adoption of Accuray's versatile systems are
constantly proven to provide comprehensive treatment solutions that serve the
full spectrum of radiation oncology patients."
For more information of Hong Kong Adventist Oncology Center, please visit
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range
of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited,
to clinical applications, clinical results, patient outcomes, and the
Company's leadership position in radiation oncology innovation.
Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from expectations, including risks
detailed from time to time under the heading "Risk Factors" in the company's
report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs
filed on November 8, 2012 & February 6, 2013, and as updated periodically by
our other filings. Forward-looking statements speak only as of the date the
statements are made and are based on information available to the Company at
the time those statements are made and/or management's good faith belief as of
that time with respect to future events. The Company assumes no obligation to
update forward-looking statements to reflect actual performance or results,
changes in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
Accordingly, investors should not place undue reliance on any forward-looking
SOURCE Accuray Incorporated
Contact: Rebecca Phillips, Public Relations Manager, Accuray, +1-408-716-4773,
email@example.com, Kaman Ng, Manager, Marketing Communications (APAC),
Press spacebar to pause and continue. Press esc to stop.